Company intelligence / Profile preview

BioAmp Diagnostics

San Carlos, California, United Statesbioampdx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

BioAmp Diagnostics has developed a chemistry-based, instrument-free diagnostic platform called DETECT that delivers actionable results for antibiotic resistance within minutes. Their initial application targets complicated urinary tract infections, aiming to enable evidence-based and rapid selection of effective antibiotics. The company’s technology is currently in advanced development and validation stages but not yet commercially launched.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic tool (Chemistry-based)
Industry: Protein Biomarker Diagnostics

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025. Notable support from accelerators and grant agencies such as the National Science Foundation and Illumina Accelerator

Beyond the preview

Go deeper on BioAmp Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioAmp Diagnostics.

Explore the full profile